Harnessing Immunology to Fight Disease

Harnessing Immunology to Fight Disease

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate truly novel medicines to treat significant unmet needs in cancer and infectious disease. Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies to redirect immune cells or drugs.

The company’s innovative products target post-translational modifications of proteins and lipids. For the vaccines this includes citrullination and homocitrullination of proteins, whereas the monoclonal antibodies target the glycans or sugars on proteins and/or lipids.


A driver in the vaccine portfolio is Moditope®, a completely novel class of cancer vaccines that induce potent CD4 cytotoxic T cells that seek out and destroy cancer cells by targeting citrullinated or homocitrullinated proteins.


ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer as well as the development of a next-generation, potentially pan-coronavirus, vaccine against SARS-CoV-2, the virus that causes COVID-19.










The GlyMab® platform is being used to discover and develop a portfolio of innovative anti-cancer monoclonal antibodies (mAbs) that target sugar motifs (glycans) present on lipids and/or proteins. These GlyMab® mAbs have ultra-high specificity and are expected to have utility in a wide range of cancers.


The AvidiMab® platform is a highly versatile approach that has been designed to enhance the potency and efficacy of any clinical antibody or antibody-based product (including those based on the ImmunoBody® platform).